Capital Fund Management S.A. Makes New $12.08 Million Investment in IQVIA Holdings Inc. (NYSE:IQV)

Capital Fund Management S.A. acquired a new position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 61,482 shares of the medical research company's stock, valued at approximately $12,082,000.

Other large investors also recently modified their holdings of the company. Pine Valley Investments Ltd Liability Co boosted its holdings in shares of IQVIA by 0.5% during the third quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company's stock worth $2,247,000 after acquiring an additional 50 shares during the period. Howard Capital Management Inc. boosted its stake in IQVIA by 4.9% in the 4th quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company's stock valued at $225,000 after purchasing an additional 54 shares during the period. Wealth Enhancement Advisory Services LLC increased its position in IQVIA by 1.0% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company's stock worth $1,068,000 after buying an additional 56 shares during the period. Cypress Wealth Services LLC lifted its holdings in shares of IQVIA by 4.8% during the fourth quarter. Cypress Wealth Services LLC now owns 1,243 shares of the medical research company's stock worth $244,000 after buying an additional 57 shares in the last quarter. Finally, Harbor Investment Advisory LLC boosted its position in shares of IQVIA by 4.7% in the fourth quarter. Harbor Investment Advisory LLC now owns 1,286 shares of the medical research company's stock valued at $253,000 after acquiring an additional 58 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Price Performance

IQV stock traded down $3.79 during mid-day trading on Thursday, hitting $144.65. The company had a trading volume of 1,242,453 shares, compared to its average volume of 1,392,426. The company has a 50-day moving average price of $178.83 and a 200 day moving average price of $198.11. IQVIA Holdings Inc. has a 12-month low of $135.97 and a 12-month high of $252.88. The company has a market capitalization of $25.50 billion, a price-to-earnings ratio of 19.28, a P/E/G ratio of 1.99 and a beta of 1.46. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV - Get Free Report) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analyst Weigh In

IQV has been the subject of several analyst reports. StockNews.com cut IQVIA from a "buy" rating to a "hold" rating in a report on Wednesday, March 12th. Citigroup reduced their price objective on shares of IQVIA from $225.00 to $210.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Truist Financial dropped their target price on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating for the company in a research report on Thursday, April 10th. Robert W. Baird reduced their price target on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 21st. Finally, UBS Group lowered their price objective on shares of IQVIA from $260.00 to $255.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Six investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, IQVIA presently has a consensus rating of "Moderate Buy" and a consensus price target of $241.50.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.